SCHEMBL5136576

SCHEMBL5136576

CCCCN(Cc1ccc(OC)c(Br)c1)Cc1c(-c2ccc(OC)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
ATP4A P20648 3/20 0.38
ATP4B P51164 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
GAA P10253 4/20 0.37
TP53 P04637 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
BCHE P06276 4/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
TSHR P16473 2/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134637 0.96 C5AR1 (0.45) C5AR1ATP4AATP4BMEN1KMT2A
SCHEMBL5135620 0.94 C5AR1 (0.43) C5AR1MEN1KMT2AGAATP53
SCHEMBL5135890 0.93 C5AR1 (0.41) C5AR1MEN1KMT2AGAATP53
SCHEMBL5137661 0.92 C5AR1 (0.43) C5AR1ATP4AATP4BGAATP53
SCHEMBL5135336 0.90 C5AR1 (0.45) C5AR1MEN1KMT2AGAATP53
SCHEMBL5135871 0.90 ATP4A (0.44) C5AR1ATP4AATP4BGAATP53
SCHEMBL5137164 0.89 C5AR1 (0.44) C5AR1ATP4AATP4BGAATP53
SCHEMBL5135902 0.89 C5AR1 (0.42) C5AR1ATP4AATP4BMEN1KMT2A
SCHEMBL649655 0.88 C5AR1 (0.47) C5AR1MEN1KMT2AGAATP53
SCHEMBL5170566 0.87 CALM1 (0.43) C5AR1ATP4AATP4BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed